# FDA Approves VEPPANU, First-Ever PROTAC Protein Degrader, for ER-Positive Metastatic Breast Cancer

> fda · REPORTED · 2026-05-01

The FDA approved VEPPANU (vepdegestrant), co-developed by Arvinas and Pfizer, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following prior endocrine therapy, marking it as the first-and-only FDA-approved PROTAC protein degrader therapy. Approval came ahead of the assigned PDUFA date of June 5, 2026.

About Arvinas / Pfizer (VEPPANU): Arvinas is a clinical-stage biopharmaceutical company pioneering PROTAC protein degrader technology; VEPPANU (vepdegestrant) is its lead oncology asset co-developed with Pfizer targeting the estrogen receptor in breast cancer.

- Company: Arvinas / Pfizer (VEPPANU)
- Sector: oncology
- Primary source: https://www.sec.gov/Archives/edgar/data/0001655759/000162828026033669/arvn-20260331.htm

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.